Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Cancer Res. 2010 Feb 9;70(5):1766–1772. doi: 10.1158/0008-5472.CAN-09-3263

Figure 2.

Figure 2

PDLIM2 repression in colon cancer cells involves DNA methylation. A, RNA levels of DNMT1, DNMT3a and DNMT3b in the indicated colon cancer cells were analyzed by real-time PCR using β-actin mRNA level as a control and represented as fold induction in mRNA abundance relative to those in MCF10A cells (set as 1). The data presented are the mean ± standard deviation (n = 3). B, The indicated cell lines were treated with the DNMT inhibitor 5-aza-dC (5μM) for 48 h, followed by real-time PCR to determine relative mRNA levels of PDLIM2. Changes in PDLIM2 mRNA abundance following 5-aza-dC treatment are represented as fold induction relative to those observed in an RNA sample from mock-treated cells. C, The indicated colon cancer cell lines were treated with 5 μM 5-aza-dC or vehicle for the indicated time points, followed by cell growth assay. D, The indicated cell lines were treated with 5 μM 5-aza-dC or vehicle for 5 days, followed by the bisulfite genomic DNA sequencing as described in Material and Methods. Each circle represents a CpG site; open circles represent unmethylated CpG dimucleotides whereas filled circles represent methylated CpG sites. The ratios of the filled area in circles represent percentiles of the methylation in the CpG sites. The position of each CpG nucleotide relative to the PDLIM2 transcription initiation site (+1) is indicated at the top.